Shichuan Tang

No.312, Xihong Road
Fuzhou, 350025, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Impact of lymph node dissection on textbook outcomes in patients with intrahepatic cholangiocarcinoma: a multi-center analysis.

Impact of lymph node dissection on textbook outcomes in patients with intrahepatic cholangiocarcinoma: a multi-center analysis.

Journal: BMC gastroenterology

Published: June 01, 2026

Immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: The critical role of subgroup analyses.

Immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: The critical role of subgroup analyses.

Journal: iLIVER

Published: November 03, 2025

Prediction of Early Recurrence in Intrahepatic Cholangiocarcinoma by Interpretable Machine Learning Model: A Multicenter Cohort Study.

Prediction of Early Recurrence in Intrahepatic Cholangiocarcinoma by Interpretable Machine Learning Model: A Multicenter Cohort Study.

Journal: Journal of clinical gastroenterology

Published: July 18, 2025

EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection.

EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection.

Journal: Gut

Published: March 28, 2025

Personalized neoantigen hydrogel vaccine combined with PD-1 and CTLA-4 double blockade elicits antitumor response in liver metastases by activating intratumoral CD8+CD69+ T cells.

Personalized neoantigen hydrogel vaccine combined with PD-1 and CTLA-4 double blockade elicits antitumor response in liver metastases by activating intratumoral CD8+CD69+ T cells.

Journal: Journal for immunotherapy of cancer

Published: November 26, 2024

Hepatic Amyloidosis Without Hepatomegaly.

Hepatic Amyloidosis Without Hepatomegaly.

Journal: Digestive diseases and sciences

Published: October 20, 2024

Tumor burden score and alpha-fetoprotein level predict prognosis of patients with unresectable hepatocellular carcinoma treated with tyrosine kinase inhibitor and anti-PD-1 antibody.

Tumor burden score and alpha-fetoprotein level predict prognosis of patients with unresectable hepatocellular carcinoma treated with tyrosine kinase inhibitor and anti-PD-1 antibody.

Journal: iLIVER

Published: May 25, 2024

Personalized neoantigen vaccine enhances the therapeutic efficacy of bevacizumab and anti-PD-1 antibody in advanced non-small cell lung cancer.

Personalized neoantigen vaccine enhances the therapeutic efficacy of bevacizumab and anti-PD-1 antibody in advanced non-small cell lung cancer.

Journal: Cancer immunology, immunotherapy : CII

Published: October 20, 2023

Analysis of conditional survival in primary hepatocellular carcinoma after narrow-margin hepatectomy: a large-sample, dual-centre, retrospective study.

Analysis of conditional survival in primary hepatocellular carcinoma after narrow-margin hepatectomy: a large-sample, dual-centre, retrospective study.

Journal: HPB : the official journal of the International Hepato Pancreato Biliary Association

Published: April 05, 2022

Postoperative Adjuvant Transarterial Chemoembolization Plus Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma: a Multicentre Retrospective Study.

Postoperative Adjuvant Transarterial Chemoembolization Plus Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma: a Multicentre Retrospective Study.

Journal: Journal of hepatocellular carcinoma

Published: December 04, 2021

Showing 1-10 of 10

Last Updated: 09/26/2026